Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: ghettogoulash who wrote (62851)	9/30/2024 3:46:52 PM
From: ghettogoulash	Respond to of 63324

SEC: "the results no longer show a significant difference between placebo, 50 mg, and 100 mg." This does not align with data generated by Quanterix in the same patients. Quanterix shows clear separation in pTau: placebo skewed to positive, drug arms skewed to negative. (See below) Technically, the company could have just fabricated data points on this 2021 AAIC poster, so believe that if you wish. Also note that the SEC evidence apparently was not convincing enough to the DOJ to add it to Wang's indictment according to Nachtrab, at least not yet.